Please check your internet connection and try again.
# Sompraz HP (Pantoprazole)
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Gastroesophageal reflux disease (GERD) - erosive esophagitis
* Healing of erosive esophagitis
* Maintenance of healing of erosive esophagitis
* Pathological hypersecretory conditions, such as Zollinger-Ellison syndrome
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **GERD (symptomatic relief):** 40 mg orally once daily for up to 4 weeks.
* **Pathological Hypersecretory Conditions:** 40 mg orally or intravenously twice daily. Doses may be increased as needed. Doses greater than 100 mg daily should be administered as 40 mg orally or intravenously twice daily with the remainder administered as a single dose.
## Pediatric Dosing
* **Erosive Esophagitis (12 to 17 years):** 40 mg orally once daily for up to 8 weeks.
* **GERD (5 to 11 years):**
* **Body weight < 40 kg:** 20 mg orally once daily for up to 8 weeks.
* **Body weight ≥ 40 kg:** 40 mg orally once daily for up to 8 weeks.
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose is 40 mg orally or intravenously.
## Contraindications
* Known hypersensitivity to pantoprazole or any of its components.
## Adverse Effects
* **Common:** Diarrhea, headache, dizziness, abdominal pain, nausea, vomiting.
* **Serious:** Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia (can be severe), vitamin B12 deficiency, potential for increased risk of pneumonia.
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Antiretrovirals (e.g., rilpivirine, atazanavir), antifungals (e.g., ketoconazole, itraconazole, posaconazole), iron salts, certain tyrosine kinase inhibitors (e.g., erlotinib, gefitinib). Pantoprazole may decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** May increase levels of drugs metabolized by CYP2C19.
* **CYP3A4 substrates:** May increase levels of drugs metabolized by CYP3A4.
## Monitoring
* Electrolytes (especially magnesium), vitamin B12 levels, bone mineral density with long-term use.
* Monitor for signs and symptoms of C. difficile-associated diarrhea.
## Clinical Pearls
* Administer orally 30 to 60 minutes before a meal.
* IV formulation requires reconstitution and dilution; follow manufacturer instructions.
* Long-term use is associated with increased risks of fractures, hypomagnesemia, and vitamin B12 deficiency. Consider the lowest effective dose for the shortest duration necessary.
* For IV administration, avoid concomitant use with other drugs that may cause electrolyte disturbances or have CNS effects.
***
**Disclaimer:** This information is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified healthcare provider to ensure the information is accurate, complete, and appropriate for your specific circumstances. Always verify current prescribing information and guidelines before making any treatment decisions.
